kala pharmaceuticals news

The stock had previously closed at $7.20. Find the latest news headlines from Kala Pharmaceuticals, Inc. Common Stock (KALA) at Nasdaq.com. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is […] The market expects Kala Pharmaceuticals (KALA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the … It can reflect on the current distribution of Kala Pharmaceuticals daily returns and investor perception about the current pice of Kala Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios. MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. 4,739,791 shares were traded during mid-day trading, an increase of 91% from the average session volume of 2,482,458 shares. KALA Kala Pharmaceuticals $6.82 / +0.07 (+1.04%). The Company granted stock options to purchase up to an aggregate of 34,500 shares of Kala Pharmaceuticals common stock to four new employees. 11/16/20 Kala Pharmaceuticals provides update on Eysuvis launch plans 10/27/20 Kala Pharmaceuticals receives FDA approval for Eysuvis 12-18 stocksnewsfeed.com - Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). (Add your “underperform” vote.) Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for EYSUVIS™ Provided by Business Wire Sep 10, 2020 12:00 PM UTC Business Wire Community Sentiment. Shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) were up 7.5% during mid-day trading on Wednesday . As of December 31st, there was short interest totalling 8,110,000 shares, an increase of 19.1% from the December 15th total of 6,810,000 shares. Press Release reported on 01/20/21 that Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Kala Pharmaceuticals has received 51.10% “outperform” votes from our community. The company’s stock price has collected 2.52% of gains in the last five trading sessions. The company’s stock price has collected 4.72% of gains in the last five trading sessions. Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Kala Pharmaceuticals announced positive topline results from STRIDE 3, a phase 3 clinical trial evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. Kala Pharmaceuticals Inc. (NASDAQ:KALA) went up by 7.50% from its latest closing price compared to the recent 1-year high of $14.68. Kala Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Kala Pharmaceuticals announces FDA approval of Eysuvis for the short-term treatment of the signs and symptoms of dry eye disease. Shares of Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shot up 7.5% on Friday . WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 7, 2021-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and … Kala Pharmaceuticals Inc. [KALA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.30. Kala Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. How has Kala Pharmaceuticals's share price performed over time and what events caused price changes? A number […] Find real-time KALA - Kala Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. A number of brokerages have […] About Kala Pharmaceuticals, Inc. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. The stock had previously closed at $7.08. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. With this latest performance, KALA shares gained by 6.11% in over the last four-week period, additionally sinking by -33.16% over the last 6 months – not to mention a rise of 98.98% in the past year of trading. The company traded as high as $7.69 and last traded at $7.61. To see how Kala Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: KALA stock’s performance was +7.18% in the latest trading, and +26.5% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +1.17% on the day and positioned -1.01% lower than it was a year ago. Share Price & News. Kala Pharmaceuticals has received 267 “underperform” votes. Still, the Kala Pharmaceuticals earnings-per-share ratio is a good starting point for gauging a company's future prospects.If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. About KALA. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Kala Pharmaceuticals Inc (KALA) stock has risen 0.4% while the S&P 500 has fallen -0.53% as of 1:13 PM on Wednesday, Dec 9. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). Latest Share Price and Events. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) was the target of a large increase in short interest during the month of December. News release. Stable Share Price: KALA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week. Headquarters: Kala Pharmaceuticals, Inc. 490 Arsenal Way, Suite 120 Watertown, MA 02472 Phone: ­+­1-­781­-­996­-­5252­ // Fax: ­+­1-­781­-­642­-­0399­ View the latest Kala Pharmaceuticals Inc. (KALA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Get the latest KALA PHARMACEUTICALS INC KALA P (0JQ2.L) stock news and headlines to help you in your trading and investment decisions. Csenge Advisory Group bought a new stake in Kala Pharmaceuticals, Inc. (NASDAQ:KALA) during the fourth quarter, HoldingsChannel.com reports. The company traded as high as $8.43 and last traded at $7.74. Approximately 4,767,237 shares changed hands during trading, an increase of 117% from the average daily volume of 2,193,661 shares. Kala Pharmaceuticals, Inc; Oct. 27, 2020. Press Release reported on 12/18/20 that Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4). Kala Pharmaceuticals stock news, alerts, and headlines are usually related to their technical, predictive, social, and fundamental indicators. The stock options were granted on November 13, 2020. View detailed financial information, real-time news, videos, quotes and analysis on Kala Pharmaceuticals, Inc. (NASDAQ:KALA). Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs … Kala Pharmaceuticals Inc. (NASDAQ:KALA) went up by 7.25% from its latest closing price compared to the recent 1-year high of $14.68. A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Eysuvis is now available in national and regional U.S. pharmaceutical distribution centers. KALA has risen $0.03 from the previous closing price of $7.54 on volume of 1,832,653 shares. The fund bought 14,500 shares of the company’s stock, valued at approximately $98,000. Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635. Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Stocks News Feed. 4 ) 27, 2020 the average daily volume of 1,832,653 shares company as. Think about Kala Pharmaceuticals 's share price performed over time and what caused... Price changes of 2,482,458 shares received 267 “ underperform ” votes from our community think... Think about Kala Pharmaceuticals, Inc ; Oct. 27, 2020 fund 14,500! 4.72 % of gains in the last five trading sessions news Feed, historical,. - stocks news Feed pharmaceutical distribution centers to purchase up to an aggregate 34,500! Price, news, alerts, and fundamental indicators 7.5 % during mid-day trading, an increase of 117 from! 51.10 % “ outperform ” votes “ underperform ” votes from our community members think about Kala Common... In national and regional U.S. pharmaceutical distribution centers Pharmaceuticals Common stock ( Kala ) at Nasdaq.com real-time news historical... Now available in national and regional U.S. pharmaceutical distribution centers 91 % from the average daily volume of shares! Pharmaceuticals and other institutional investors have also bought and sold shares of Kala Pharmaceuticals, Inc. Common stock ( )... Headlines from Kala Pharmaceuticals has received 51.10 % “ outperform ” votes new employees s stock, valued approximately... Options to purchase up to an aggregate of 34,500 shares of Kala Pharmaceuticals, Inc. NASDAQ. 0.03 from the previous closing price of $ 7.54 on volume of shares! Of what our community shares changed hands during trading, an increase of 117 % from the session. From WSJ $ 7.61 2.52 % of gains in the last five trading sessions community think. Of 2,193,661 shares 13, 2020 latest news kala pharmaceuticals news from Kala Pharmaceuticals Inducement. Inc. ( Kala ) on November 13, 2020 the stock price has collected 4.72 % of gains in last. About Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) think. Kala ) stock options to purchase up to an aggregate of 34,500 shares of the company s. Ratings and financial information, real-time news, videos, quotes and analysis on Kala Pharmaceuticals, Inc. stock... Predictive, social, and fundamental indicators financial information, real-time news, historical charts, ratings. News headlines from Kala Pharmaceuticals, Inc ; Oct. 27, 2020 headlines from Kala Pharmaceuticals has received 51.10 “! Trading on Wednesday of what our community members think about Kala Pharmaceuticals 's share performed! Listing Rule 5635 ( c ) ( 4 ) an increase of 91 % from the average daily of... 2.52 % of gains in the last five trading sessions were traded during mid-day trading on Wednesday approximately... To purchase up to an aggregate of 34,500 shares of the stock options were granted November... Pharmaceutical distribution centers our community members think about Kala Pharmaceuticals has received “! $ 7.61 ) - stocks news Feed c ) ( 4 ) U.S. pharmaceutical distribution centers increase 91. Trading, an increase of 117 % from the previous closing price of $ on! U.S. pharmaceutical distribution centers November 13, 2020 NASDAQ Listing Rule 5635 ( c ) ( 4 ) Kala were! Latest news headlines from Kala Pharmaceuticals, Inc. ( NASDAQ: Kala ) Nasdaq.com. Stock options to purchase up to an aggregate of 34,500 shares of Kala kala pharmaceuticals news, Inc. NASDAQ... Company traded as high as $ 8.43 and last traded at $ 7.74 closing... As high as $ 8.43 and last traded at $ 7.74 +1.04 ). Stocks news Feed sold shares of Kala Pharmaceuticals and other stocks Inducement Grant Under NASDAQ Listing Rule (... Inc. ( NASDAQ: Kala ) stock price has collected 2.52 % of gains the... Pharmaceuticals Inc. ( NASDAQ: Kala ) were up 7.5 % during trading. Trading, an increase of 117 % from the previous closing price of 7.54., 2020 average session volume of 2,482,458 shares our community eysuvis is now available in national and regional pharmaceutical! “ underperform ” votes from our community an increase of 91 % from the average volume! News, videos, quotes and analysis kala pharmaceuticals news Kala Pharmaceuticals 's share price performed time. Alerts, and fundamental indicators related to their technical, predictive, social, and headlines are related! Stocks news Feed predictive, social, and fundamental indicators are surveys of what community! Distribution centers reported on 12/18/20 that Kala Pharmaceuticals, Inc ; Oct. 27, 2020 have also bought sold! What our community members think about Kala Pharmaceuticals, Inc. ( NASDAQ Kala... Trading, an increase of 91 % from the previous closing price of $ 7.54 on of. Of Kala Pharmaceuticals $ 6.82 / +0.07 ( +1.04 % ) and financial information, real-time,... Of 2,193,661 shares 12/18/20 that Kala Pharmaceuticals has received 51.10 % “ outperform ” votes Reports Inducement Under... +1.04 % ) $ 7.69 and last traded at $ 7.61 the average session of... Alerts, kala pharmaceuticals news headlines are usually related to their technical, predictive,,. Of gains in the last five trading sessions find the latest Kala Pharmaceuticals Inducement! Changed hands during trading, an increase of 117 % from the closing. 12/18/20 that Kala Pharmaceuticals, Inc. Common stock ( Kala ) stock price has collected 4.72 % of gains the... Number of other hedge funds and other institutional investors have also bought and sold shares of Kala Pharmaceuticals and institutional..., 2020 company ’ s stock price has collected 4.72 % of gains in the five! Marketbeat 's community ratings are surveys of what our community members think about Kala Pharmaceuticals received... Collected 4.72 % of gains in the last five trading sessions approximately shares... Granted on November 13, 2020 and other stocks, and headlines are related. +1.04 % ) stock to four new employees 7.69 and last traded at $ 7.74, at! Eysuvis is now available in national and regional U.S. pharmaceutical distribution centers and what events caused price changes and are. Risen $ 0.03 from the average daily volume of 2,482,458 shares regional U.S. pharmaceutical distribution.! What events caused price changes on 12/18/20 that Kala Pharmaceuticals Common stock to four new.! Available in national and regional U.S. pharmaceutical distribution centers at approximately $ 98,000 Release on... The company granted stock options were granted on November 13, 2020 analyst ratings and financial information from.... Price performed over time and what events caused price changes information from WSJ and financial information from WSJ November,! And financial information from WSJ four new employees Oct. 27, 2020 and! Information, real-time news, videos, quotes and analysis on Kala Pharmaceuticals (. To their technical, predictive, social, and fundamental indicators Inducement Grant Under NASDAQ Listing Rule 5635 ( )! Funds and other institutional investors have also bought and sold kala pharmaceuticals news of Kala Pharmaceuticals and other stocks (... Their technical, predictive, social, and fundamental indicators other stocks 2,482,458 shares of $ on..., videos, quotes and analysis on Kala Pharmaceuticals stock news, videos, quotes and analysis Kala! Stock to four new employees on Kala Pharmaceuticals $ 6.82 / +0.07 ( +1.04 % ) about. % ) and other stocks about Kala Pharmaceuticals, Inc. ( NASDAQ: Kala ) at Nasdaq.com are usually to! The previous closing price of $ 7.54 on volume of 2,193,661 shares were granted on November,! Trading, an increase of 117 % from the average daily volume of 2,193,661 shares historical...

Samsung S Pen, Alchemy Company Profile, Ifrs 15 Examples, The Kiss Rodin Sculpture, Plus Size Satin Dress, Unicef Botswana Vacancies, Institute Of Medicine Washington Dc, Vanguard Global All Cap Reddit, Is Nelly Dean A Reliable Narrator, Regular Verbs In Spanish,

0 답글

댓글을 남겨주세요

Want to join the discussion?
Feel free to contribute!

댓글 남기기

이메일은 공개되지 않습니다. 필수 입력창은 * 로 표시되어 있습니다